Table 2.
Demographics.
| Characteristics | Patients | |
|---|---|---|
| Total number of patients | 41 | |
|
| ||
| Age (years) | ||
| Mean | 57.1 | |
| Range | (30–71) | |
|
| ||
| Gender | ||
| Female | 15 (37%) | |
| Male | 26 (63%) | |
|
| ||
| ECOG performance status | N: 41 | |
|
| ||
| 0 | 23 | |
| 1 | 14 | |
| 2 | 4 | |
|
| ||
| Tumour type | DE (N: 25) | MTD (N: 16) |
|
| ||
| Solid tumours, total | 15 | 0 |
| Colorectal adenocarcinoma | 1 | 0 |
| Non-small cell lung cancer | 1 | 0 |
| Renal pelvis carcinosarcoma | 1 | 0 |
| Pancreas adenocarcinoma | 1 | 0 |
| Cholangiocarcinoma | 1 | 0 |
| Cervix cell carcinoma | 1 | 0 |
| Stromal tumour of unknown | 1 | 0 |
| Anal planocellular carcinoma | 1 | 0 |
| Ocular malignant melanoma | 3 | 0 |
| Bladder carcinoma | 1 | 0 |
| Renal carcinoma | 1 | 0 |
| Squamous cell carcinoma | 1 | 0 |
| Thyroid carcinoma | 1 | 0 |
|
| ||
| Sarcomas, total | 10 | 16 |
| Liposarcoma | 2 | 3 |
| Leiomyosarcoma | 2 | 5 |
| Chondrosarcoma | 1 | 3 |
| Angiosarcoma | 1 | 1 |
| Myxofibrosarcoma | 1 | 1 |
| Undif pleomorphic sarcoma | 1 | 1 |
| Rhabdomyosarcoma | 1 | 0 |
| Fibrosarcoma | 1 | 0 |
| Myogenic sarcoma | 0 | 1 |
| Synovial sarcoma | 0 | 1 |
DE: dose escalation phase I study.
MTD: maximum tolerated dose phase II study.